JP6997800B2 - 神経炎症性障害の処置に使用される小有機分子 - Google Patents

神経炎症性障害の処置に使用される小有機分子 Download PDF

Info

Publication number
JP6997800B2
JP6997800B2 JP2019557789A JP2019557789A JP6997800B2 JP 6997800 B2 JP6997800 B2 JP 6997800B2 JP 2019557789 A JP2019557789 A JP 2019557789A JP 2019557789 A JP2019557789 A JP 2019557789A JP 6997800 B2 JP6997800 B2 JP 6997800B2
Authority
JP
Japan
Prior art keywords
group
bmp
alkyl
pharmaceutical composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019557789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517678A5 (https=
JP2020517678A (ja
Inventor
アーロン カルニ
カリン ベルナデット ファインベルク
Original Assignee
メディカル リサーチ， インフラストラクチュア アンド ヘルス サービシーズ ファンド オブ ザ テル アビブ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディカル リサーチ， インフラストラクチュア アンド ヘルス サービシーズ ファンド オブ ザ テル アビブ メディカル センター filed Critical メディカル リサーチ， インフラストラクチュア アンド ヘルス サービシーズ ファンド オブ ザ テル アビブ メディカル センター
Publication of JP2020517678A publication Critical patent/JP2020517678A/ja
Publication of JP2020517678A5 publication Critical patent/JP2020517678A5/ja
Application granted granted Critical
Publication of JP6997800B2 publication Critical patent/JP6997800B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2019557789A 2017-04-26 2018-04-26 神経炎症性障害の処置に使用される小有機分子 Active JP6997800B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL251949A IL251949A0 (en) 2017-04-26 2017-04-26 Small organic molecules for use in the treatment of neuro-inflammatory diseases
IL251949 2017-04-26
PCT/IL2018/050463 WO2018198123A1 (en) 2017-04-26 2018-04-26 Small organic molecules for use in the treatment of neuroinflammatory disorders

Publications (3)

Publication Number Publication Date
JP2020517678A JP2020517678A (ja) 2020-06-18
JP2020517678A5 JP2020517678A5 (https=) 2021-04-01
JP6997800B2 true JP6997800B2 (ja) 2022-02-04

Family

ID=62454780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019557789A Active JP6997800B2 (ja) 2017-04-26 2018-04-26 神経炎症性障害の処置に使用される小有機分子

Country Status (9)

Country Link
US (2) US11103479B2 (https=)
EP (1) EP3615022B1 (https=)
JP (1) JP6997800B2 (https=)
CN (1) CN110869015B (https=)
AU (1) AU2018260535B2 (https=)
CA (1) CA3061296A1 (https=)
ES (1) ES2948767T3 (https=)
IL (2) IL251949A0 (https=)
WO (1) WO2018198123A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019122202A1 (en) * 2017-12-20 2019-06-27 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors
JP7481329B2 (ja) * 2018-06-07 2024-05-10 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
WO2020132045A1 (en) * 2018-12-19 2020-06-25 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538060A (ja) 2002-06-12 2005-12-15 ケモセントリックス， インコーポレイテッド 抗炎症性組成物および使用の方法
CN1807411A (zh) 2006-02-20 2006-07-26 中国医学科学院医药生物技术研究所 一组具有上调骨形成蛋白bmp－2表达活性的五元不饱和杂环化合物
JP2011514908A (ja) 2008-03-13 2011-05-12 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
JP2012105555A (ja) 2010-11-15 2012-06-07 Kitasato Institute 骨分化阻害剤およびその製造方法
JP2012533545A (ja) 2009-07-14 2012-12-27 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド 肝臓の増殖を増大させる方法
WO2013186777A2 (en) 2012-06-14 2013-12-19 The Medical Researth, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
JP2016515119A (ja) 2013-03-14 2016-05-26 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY109202A (en) 1992-07-10 1996-12-31 Nihon Nohyaku Co Ltd Isothiazole derivatives and processes for preparing the same as well as termite controlling agents comprising the same as active ingredient
IT1313601B1 (it) 1999-08-05 2002-09-09 Isagro Ricerca Srl Fenilpirazoli ad attivita' erbicida
EP1088822A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
US6989451B2 (en) 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
GB0306357D0 (en) 2003-03-20 2003-04-23 Astrazeneca Ab Chemical compounds
US20080249038A1 (en) 2003-10-07 2008-10-09 Quark Biotech, Inc. Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof
US20060217390A1 (en) 2005-02-24 2006-09-28 Esmir Gunic Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
US8497272B2 (en) * 2006-08-21 2013-07-30 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2008118626A2 (en) 2007-03-08 2008-10-02 Burnham Institute For Medical Research Inhibitors of jnk and methods for identifying inhibitors of jnk
US20110039900A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Isothiozoles for treating conditions of the eye
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538060A (ja) 2002-06-12 2005-12-15 ケモセントリックス， インコーポレイテッド 抗炎症性組成物および使用の方法
CN1807411A (zh) 2006-02-20 2006-07-26 中国医学科学院医药生物技术研究所 一组具有上调骨形成蛋白bmp－2表达活性的五元不饱和杂环化合物
JP2011514908A (ja) 2008-03-13 2011-05-12 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
JP2012533545A (ja) 2009-07-14 2012-12-27 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド 肝臓の増殖を増大させる方法
JP2012105555A (ja) 2010-11-15 2012-06-07 Kitasato Institute 骨分化阻害剤およびその製造方法
WO2013186777A2 (en) 2012-06-14 2013-12-19 The Medical Researth, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
JP2016515119A (ja) 2013-03-14 2016-05-26 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法

Also Published As

Publication number Publication date
CN110869015B (zh) 2023-08-18
IL269894B (en) 2022-03-01
US20210393582A1 (en) 2021-12-23
CA3061296A1 (en) 2018-11-01
EP3615022B1 (en) 2023-06-07
ES2948767T3 (es) 2023-09-18
EP3615022A4 (en) 2021-03-31
IL251949A0 (en) 2017-07-31
US11779565B2 (en) 2023-10-10
US11103479B2 (en) 2021-08-31
CN110869015A (zh) 2020-03-06
EP3615022C0 (en) 2023-06-07
AU2018260535A1 (en) 2019-10-31
US20200046680A1 (en) 2020-02-13
JP2020517678A (ja) 2020-06-18
EP3615022A1 (en) 2020-03-04
WO2018198123A1 (en) 2018-11-01
AU2018260535B2 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
US11912998B2 (en) Method of treating aging-associated cognitive impairment by reducing CCR3
JP7212781B2 (ja) 神経保護剤と組み合わせたｓａｒｍ１の阻害剤
US10626399B2 (en) Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
JP5704785B2 (ja) 免疫抑制のためのｆｌｔ３阻害剤
Zhang et al. Protective effect of melatonin on soluble Aβ1–42-induced memory impairment, astrogliosis, and synaptic dysfunction via the Musashi1/Notch1/Hes1 signaling pathway in the rat hippocampus
JP7134089B2 (ja) 老化に関連した障害を処置するための方法及び組成物
US20140142089A1 (en) Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
CN109073634B (zh) 用于诱导神经干细胞的分化和保护的组合物及使用该组合物诱导神经再生的方法
JP6997800B2 (ja) 神経炎症性障害の処置に使用される小有機分子
Tapella et al. TGF‐β2 and TGF‐β3 from cultured β‐amyloid‐treated or 3xTg‐AD‐derived astrocytes may mediate astrocyte–neuron communication
US20030082802A1 (en) Method for neural stem cell differentiation using 5ht1a agonists
WO2018183679A1 (en) Methods and compositions for modulating gene expression
Ma et al. Matrine alleviates astrogliosis through sphingosine 1-phosphate signaling in experimental autoimmune encephalomyelitis
US20170172987A1 (en) Isoxazole treatments for frontotemporal dementia
JP6709493B2 (ja) 進行性骨化性線維異形成症治療剤
JP2023505063A (ja) トレフォイル因子ファミリーメンバー２モジュレーターによる老化関連障害処置のための方法および組成物
RU2846703C2 (ru) Композиции для предотвращения или лечения амиотрофии шарко-мари-тута (шмт)
McPhail Targeting neuroinflammation in mTORC1 driven brain tumours
US20180298102A1 (en) Methods and compositions for treating aging-associated impairments
WO2025249409A1 (ja) 髄鞘異常関連疾患治療剤の有効成分として有用な化合物
WO2025054309A1 (en) Methods of identifying and treating patients having neurodegenerative disease based on plasma biomarker levels
JP2017132742A (ja) Ａβオリゴマー特異的抗体の新規薬理用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210217

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211116

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211217

R150 Certificate of patent or registration of utility model

Ref document number: 6997800

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250